[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE486088T1 - Hiv-impfstoff - Google Patents

Hiv-impfstoff

Info

Publication number
ATE486088T1
ATE486088T1 AT07722719T AT07722719T ATE486088T1 AT E486088 T1 ATE486088 T1 AT E486088T1 AT 07722719 T AT07722719 T AT 07722719T AT 07722719 T AT07722719 T AT 07722719T AT E486088 T1 ATE486088 T1 AT E486088T1
Authority
AT
Austria
Prior art keywords
composition
immunodeficiency virus
human immunodeficiency
medicament
manufacture
Prior art date
Application number
AT07722719T
Other languages
English (en)
Inventor
Anders Fomsgaard
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of ATE486088T1 publication Critical patent/ATE486088T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07722719T 2006-06-01 2007-06-01 Hiv-impfstoff ATE486088T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600750 2006-06-01
PCT/DK2007/050066 WO2007137591A2 (en) 2006-06-01 2007-06-01 Hiv vaccine

Publications (1)

Publication Number Publication Date
ATE486088T1 true ATE486088T1 (de) 2010-11-15

Family

ID=38617522

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07722719T ATE486088T1 (de) 2006-06-01 2007-06-01 Hiv-impfstoff

Country Status (4)

Country Link
EP (1) EP2021356B1 (de)
AT (1) ATE486088T1 (de)
DE (1) DE602007010127D1 (de)
WO (1) WO2007137591A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0805356D0 (en) * 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
JP2014501225A (ja) * 2010-09-27 2014-01-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
EP2812016A2 (de) * 2012-02-12 2014-12-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Zelluläre apobec3-proteine und modulatoren davon zur regulierung von dna-reparaturverfahren und behandlung proliferativer erkrankungen
EP2745845A1 (de) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Verfahren zur Vorbeugung oder Behandlung einer HIV-Infektion
FR3086534B1 (fr) * 2018-10-01 2020-11-06 Univ Bordeaux Methode pour traiter une infection par le virus de l'immunodeficience humaine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
JP2003523365A (ja) * 2000-01-28 2003-08-05 スタテンズ セーラム インスティテュート Ｈｉｖ感染の診断及びコントロールのためのｈｉｖペプチド及びそれをエンコードする核酸

Also Published As

Publication number Publication date
WO2007137591A3 (en) 2008-03-20
EP2021356B1 (de) 2010-10-27
EP2021356A2 (de) 2009-02-11
WO2007137591A2 (en) 2007-12-06
WO2007137591A8 (en) 2009-07-30
DE602007010127D1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
JP2012509340A5 (de)
Soliman et al. Mechanisms of HIV-1 control
EP3967323A3 (de) Hiv-impfstoff
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
SI2709613T1 (en) Procedures for the treatment of HCV
JP2018524335A5 (de)
ATE486088T1 (de) Hiv-impfstoff
JP2018521643A5 (de)
EA201270108A1 (ru) Формирование полиспецифического t-клеточного ответа против вич у человека
CA2794632A1 (en) Bifunctional molecules for inactivating hiv and blocking hiv entry
BR112023002164A2 (pt) Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico
MX2012004409A (es) Proteina recombinante de humano cc10 para el tratamiento de la influenza.
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
SG170825A1 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
Sadat Larijani et al. A shot at dendritic cell-based vaccine strategy against HIV-1
MX354571B (es) Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1).
JP2011521648A5 (de)
US20140011735A1 (en) Antiviral composition
NZ595060A (en) Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
WO2010041237A3 (en) Cyclic v3 peptides for anti hiv-1 vaccine
CY1115541T1 (el) Μεταλλαγμενη πρωτεϊνη τατ ουι για την προληψη ή την θεραπευτικη αντιμετωπιση του αids

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties